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Abstract 19 
Epithelial cells that lose attachment to the extracellular matrix undergo a specialized form of 20 
apoptosis called anoikis. Here, using large-scale RNA interference (RNAi) screening, we find 21 
that KDM3A, a histone H3 lysine 9 (H3K9) mono- and di-demethylase, plays a pivotal role in 22 
anoikis induction. In attached breast epithelial cells, KDM3A expression is maintained at low 23 
levels by integrin signaling. Following detachment, integrin signaling is decreased resulting in 24 
increased KDM3A expression. RNAi-mediated knockdown of KDM3A substantially reduces 25 
apoptosis following detachment and, conversely, ectopic expression of KDM3A induces cell 26 
death in attached cells. We find that KDM3A promotes anoikis through transcriptional activation 27 
of BNIP3 and BNIP3L, which encode pro-apoptotic proteins. Using mouse models of breast 28 
cancer metastasis we show that knockdown of Kdm3a enhances metastatic potential. Finally, we 29 
find defective KDM3A expression in human breast cancer cell lines and tumors. Collectively, our 30 
results reveal a novel transcriptional regulatory program that mediates anoikis. 31 
 32 
Impact Statement  33 
A large-scale RNA interference screen uncovers a new transcriptional regulatory program 34 
involving the histone H3 demethylase KDM3A, which mediates detachment-induced apoptosis 35 
(anoikis) in breast epithelial cells. 36 
  37 
 3
Introduction 38 
Epithelial cells that lose attachment to the extracellular matrix (ECM), or attach to an 39 
inappropriate ECM, undergo a specialized form of apoptosis called anoikis. Anoikis has an 40 
important role in preventing oncogenesis, particularly metastasis, by eliminating cells that lack 41 
proper ECM cues (Simpson et al., 2008; Zhu et al., 2001). Anoikis also functions to prevent the 42 
invasion of tumor cells into the luminal space, which is a hallmark of epithelial tumors (Debnath 43 
et al., 2002). In general, epithelial-derived cancers, such as breast cancer, develop resistance to 44 
anoikis (reviewed in Schwartz, 1997). Several signaling pathways have been shown to regulate 45 
anoikis (reviewed in Paoli et al., 2013). In particular, anoikis is suppressed by integrin signaling, 46 
which functions through focal adhesion kinase (FAK), an activator of the RAF/MEK/ERK 47 
pathway (King et al., 1997). FAK signaling is active in attached cells and is inactive following 48 
detachment (Frisch et al., 1996). Anoikis is also suppressed by integrin-mediated, ligand 49 
independent activation of the epidermal growth factor receptor (EGFR) signaling pathway (Moro 50 
et al., 1998), which, like FAK, also stimulates RAF/MEK/ERK activity.  51 
These cell signaling pathways have been found to regulate the levels of BIM (also called 52 
BCL2L11) and BMF, two pro-apoptotic members of the BCL2 family of apoptosis regulators 53 
previously shown to contribute to anoikis (Reginato et al., 2003; Schmelzle et al., 2007). 54 
However, depletion of BIM or BMF diminishes but does not completely prevent anoikis 55 
(Reginato et al., 2003; Schmelzle et al., 2007), suggesting the existence of other factors and 56 
regulatory pathways that can promote anoikis. Moreover, the basis of anoikis resistance remains 57 
to be determined and to date has not been linked to alterations in expression or activity of BIM or 58 
BMF. 59 
 60 
Results and discussion 61 
To investigate the possibility that there are additional factors and regulatory pathways that 62 
promote anoikis, we performed a large-scale RNA interference (RNAi) screen for genes whose 63 
loss of expression confer anoikis resistance. The screen was performed in MCF10A cells, an 64 
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immortalized but non-transformed human breast epithelial cell line that has been frequently used 65 
to study anoikis (see, for example, Huang et al., 2010; Reginato et al., 2003; Schmelzle et al., 66 
2007; Taube et al., 2006). A genome-wide human small hairpin RNA (shRNA) library 67 
comprising ~62,400 shRNAs directed against ~28,000 genes (Silva et al., 2003; Silva et al., 68 
2005) was divided into 10 pools, which were packaged into retroviral particles and used to stably 69 
transduce MCF10A cells. Following selection, the cells were divided into two populations, one 70 
of which was plated on poly-2-hydroxyethylmethacrylate (HEMA)-coated plates for 10 days to 71 
inhibit cell attachment to matrix, and another that was cultured attached to matrix for 10 days as 72 
a control (Figure 1A). Surviving cells were selected and shRNAs identified by deep sequencing. 73 
Bioinformatic analysis of the two populations identified 26 shRNAs whose abundance was 74 
significantly enriched >500-fold following detachment (Figure 1–source data 1); such shRNAs 75 
presumably confer upon MCF10A cells a selective advantage by protecting them from 76 
undergoing anoikis.  77 
 To validate candidates isolated from the primary screen, we selected the top 20 most 78 
highly enriched shRNAs and analyzed them in an independent assay for their ability to confer 79 
resistance to anoikis. Briefly, MCF10A cells were transduced with a single shRNA, detached 80 
from matrix for 96 hours, and analysed for cell death by annexin V staining. As expected, 81 
knockdown of BIM, a positive control, decreased cell death following detachment compared to 82 
the control non-silencing (NS) shRNA (Figure 1B and Figure 1–figure supplement 1). Of the 20 83 
candidate shRNAs tested, five reduced the level of detachment-induced apoptosis compared to 84 
the NS shRNA, indicating they conferred anoikis resistance (Figure 1B and Figure 1–figure 85 
supplement 1). Similar results were obtained using a second, unrelated shRNA directed against 86 
the same target gene (Figure 1–figure supplement 2). Quantitative RT-PCR (qRT-PCR) 87 
confirmed in all cases that expression of the target gene was decreased in the knockdown cell 88 
line (Figure 1–figure supplement 3).  89 
One of the top scoring validated candidates was KDM3A (Figure 1–source data 1), a 90 
histone demethylase that specifically demethylates mono-methylated (me1) and di-methylated 91 
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(me2) histone H3 lysine 9 (H3K9) (Yamane et al., 2006). H3K9 methylation is a transcriptional 92 
repressive mark, and the identification of KDM3A raised the intriguing possibility that induction 93 
of anoikis involves transcriptional activation of specific genes through H3K9me1/2 94 
demethylation. Therefore, our subsequent experiments focused on investigating the role of 95 
KDM3A in anoikis.  96 
We asked whether ectopic expression of KDM3A was sufficient to promote cell death in 97 
attached cells. MCF10A cells were transduced with a retrovirus expressing wild-type KDM3A, a 98 
catalytically inactive KDM3A mutant [KDM3A(H1120G/D1122N)] (Beyer et al., 2008) or, as a 99 
control, empty vector (Figure 1–figure supplement 4), and then treated with puromycin for 10 100 
days at which time viability was assessed by crystal violet staining. The results of Figure 1C 101 
show that ectopic expression of wild-type KDM3A but not KDM3A(H1120G/D1122N) greatly 102 
reduced MCF10A cell viability. Collectively, the results of Figure 1 demonstrate that KDM3A is 103 
necessary and sufficient for efficient induction of anoikis in breast epithelial cells. 104 
We next examined the relationship between KDM3A expression and induction of 105 
anoikis. The immunoblot of Figure 2A shows that KDM3A protein levels were undetectable in 106 
attached MCF10A cells, but robustly increased in a time-dependent manner following 107 
detachment. The qRT-PCR analysis of Figure 2B shows that an increase in KDM3A expression 108 
following detachment was also detected at the mRNA level. 109 
We next sought to understand the basis for the increase in KDM3A levels following 110 
detachment. As mentioned above, anoikis is suppressed by integrin signaling, which functions 111 
through FAK, a regulator of the RAF/MEK/ERK pathway (Frisch et al., 1996; King et al., 1997). 112 
Detachment causes a disruption in integrin–ECM contacts, resulting in a loss of FAK signaling 113 
in the detached cells (Frisch and Francis, 1994; Frisch et al., 1996), which we observed have 114 
elevated KDM3A levels (see Figures 2A and 2B). We therefore tested whether restoration of 115 
integrin signaling in detached cells would block the increase in KDM3A levels. The results of 116 
Figure 2C show that the addition of Matrigel basement membrane-like matrix, which restores 117 
integrin signaling, to detached cells markedly blocked the elevated levels of the BIM isoform 118 
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BIMEL, as expected, and KDM3A. Treatment of MCF10A cells with a FAK inhibitor increased 119 
the levels of KDM3A protein (Figure 2D) and mRNA (Figure 2–figure supplement 1A). Thus, 120 
the increase in KDM3A levels upon detachment of MCF10A cells is due, at least in part, to the 121 
loss of integrin/FAK signaling.   122 
We next analyzed the relationship between the EGFR signaling pathway and KDM3A 123 
levels. In the first set of experiments, we ectopically expressed either EGFR or a constitutively 124 
active MEK mutant, MEK2(S222D/S226D) (MEK2DD) (Voisin et al., 2008), both of which 125 
have been previously shown to block anoikis in detached cells (Reginato et al., 2003). Consistent 126 
with these previous results, Figure 2E shows that in detached MCF10A cells, expression of either 127 
EGFR or MEK2DD substantially decreased the level of BIMEL (Reginato et al., 2003). 128 
Expression of either EGFR or MEK2DD also decreased the levels of KDM3A in detached 129 
MCF10A cells. Conversely, KDM3A protein levels were increased in attached MCF10A cells 130 
treated with the EGFR inhibitor gefitinib (Barker et al., 2001; Ward et al., 1994) (Figure 2F) or 131 
the MEK inhibitor U0126 (Favata et al., 1998) (Figure 2G). Both gefitinib and U0126 treatment 132 
also resulted in increased KDM3A mRNA levels (Figure 2–figure supplement 1B,C).  133 
The results described above suggest a model in which following detachment, the 134 
resulting increase in KDM3A demethylates H3K9me1/2 to stimulate expression of one or more 135 
pro-apoptotic genes. To test this model and identify pro-apoptotic KDM3A target genes, we took 136 
a candidate-based approach and analyzed expression of a panel of genes encoding pro-apoptotic 137 
BCL2 proteins (Boyd et al., 1994; Lomonosova and Chinnadurai, 2008; Matsushima et al., 1998) 138 
in attached MCF10A cells and detached cells expressing a NS or KDM3A shRNA. We sought to 139 
identify genes whose expression increased following detachment in control but not in KDM3A 140 
knockdown cells. We found that expression of the vast majority of genes encoding pro-apoptotic 141 
BCL2 proteins were unaffected by detachment in MCF10A cells (Figure 3A and Figure 3–figure 142 
supplement 1). Consistent with previous results (Reginato et al., 2003; Schmelzle et al., 2007), 143 
expression of BIM and BMF were increased upon detachment. However, knockdown of KDM3A 144 
did not decrease expression of either BIM or BMF. By contrast, following detachment, 145 
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expression of BNIP3 and BNIP3L increased, and were the only genes whose expression was 146 
diminished more than 2-fold by KDM3A knockdown (Figure 3A and Figure 3–figure supplement 147 
1). We therefore performed a series of experiments to determine whether BNIP3 and BNIP3L are 148 
critical KDM3A target genes that mediate anoikis. 149 
In the first set of experiments we analyzed BNIP3 and BNIP3L protein levels during 150 
anoikis induction. The immunoblot of Figure 3B shows that BNIP3 and BNIP3L levels were 151 
very low in attached cells and substantially increased following detachment, with a time course 152 
similar to that of detachment-induced KDM3A expression (see Figure 2A). The chromatin 153 
immunoprecipitation (ChIP) experiment of Figure 3C shows that KDM3A was bound to the 154 
BNIP3 and BNIP3L promoters in detached but not attached cells. Moreover, the levels of 155 
H3K9me2 (Figure 3D) and H3K9me1 (Figure 3–figure supplement 2) on the BNIP3 and BNIP3L 156 
promoters were greatly diminished following detachment, which was counteracted by 157 
knockdown of KDM3A. Conversely, overexpression of KDM3A but not 158 
KDM3A(H1120G/D1122N) in attached MCF10A cells resulted in decreased levels of H3K9me1 159 
and H3K9me2 on the BNIP3 and BNIP3L promoters and increased expression of BNIP3 and 160 
BNIP3L (Figure 3–figure supplement 3). Finally, knockdown of BNIP3 or BNIP3L (Figure 3–161 
figure supplement 4) resulted in decreased apoptosis following detachment (Figure 3E and 162 
Figure 3–figure supplement 5). To further establish the pro-apoptotic role of BNIP3 and BNIP3L 163 
in MCF10A cells, we ectopically expressed BNIP3, BNIP3L or both in attached cells (Figure 3–164 
figure supplement 6). Figure 3F shows that moderate cell death was observed upon ectopic 165 
expression of either BNIP3 or BNIP3L, but substantial cell death occurred in cells ectopically 166 
expressing both BNIP3 and BNIP3L. Collectively, these results establish BNIP3 and BNIP3L as 167 
critical KDM3A target genes that mediate anoikis (Figure 3G).   168 
We considered the possibility that decreased KDM3A expression may contribute to 169 
anoikis resistance in breast cancer cells and performed a series of experiments to test this idea. 170 
We first analyzed a panel of human breast cancer cell lines (BT549, MDA-MB-231, MCF7, 171 
SUM149 and T47D) comparing, as a control, anoikis-sensitive MCF10A cells. As expected, 172 
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detachment-induced apoptosis was significantly diminished in breast cancer cell lines compared 173 
to MCF10A cells, indicative of anoikis resistance (Figure 4A and Figure 4–figure supplement 1). 174 
Moreover, following detachment of the breast cancer cell lines, induction of KDM3A at both the 175 
protein (Figure 4B) and mRNA (Figure 4C) levels was much lower than that observed in 176 
MCF10A cells. However, ectopic expression of KDM3A was sufficient to induce apoptosis in 177 
each of the five breast cancer cell lines (Figure 4D). Collectively, these results indicate that 178 
anoikis-resistance of human breast cancer cells is due, at least in part, to inefficient induction of 179 
KDM3A following detachment. 180 
We next analyzed KDM3A expression in human breast cancer patient samples. 181 
Interrogation of the Oncomine database (Rhodes et al., 2007) revealed decreased expression 182 
levels of KDM3A in several breast cancer datasets (Figure 4–figure supplement 2). To confirm 183 
these in silico results, we analyzed KDM3A expression by qRT-PCR in a series of human breast 184 
cancer patient samples. The results of Figure 4E show that compared to normal breast epithelium 185 
KDM3A expression was significantly decreased in a high percentage of breast cancers. Likewise, 186 
basal KDM3A expression levels were also diminished in most human breast cancer cell lines 187 
analyzed (Figure 4–figure supplement 3).   188 
 Finally, we performed a series of experiments to determine whether KDM3A affects 189 
metastatic potential. We first asked whether depletion of KDM3A would promote anoikis 190 
resistance in vivo using a mouse pulmonary survival assay. Briefly, immortalized but non-191 
transformed mouse mammary epithelial CLS1 cells were stably transduced with an NS or 192 
Kdm3a shRNA (Figure 4–figure supplement 4) and injected into the tail vein of syngeneic mice. 193 
After 2 weeks, the lungs were harvested, dissociated into single cell suspensions, and plated in 194 
media containing puromycin to select for cells expressing the shRNA. The surviving colonies 195 
were visualized by crystal violet staining and quantified. The results of Figure 4F show that 196 
Kdm3a knockdown significantly increased the number of cells that survived in the mouse lung 197 
relative to the control NS shRNA. 198 
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 In a second set of experiments, we used a well-characterized mouse breast cancer 199 
carcinoma progression series comprising isogenic cell lines with increasing metastatic potential: 200 
(1) non-invasive and non-metastatic 67NR cells, which form primary tumors, (2) invasive and 201 
non-metastatic 4T07 cells, which enter the circulation but fail to establish secondary tumors, and 202 
(3) highly metastatic 4T1 cells, which disseminate widely and colonize distant organ sites 203 
(Aslakson and Miller, 1992). qRT-PCR analysis revealed decreased Kdm3a expression in cell 204 
lines with greater metastatic potential (Figure 4–figure supplement 5). We expressed either a 205 
control NS shRNA or a Kdm3a shRNA in 67NR cells containing a luciferase reporter gene 206 
(Figure 4–figure supplement 6). Cells were injected into the tail veins of three syngeneic mice 207 
and pulmonary metastases were visualized by live animal imaging after 5 weeks. The results of 208 
Figure 4G show, as expected, that control 67NR cells failed to form pulmonary metastases in any 209 
of the three mice analyzed. By contrast, Kdm3a knockdown 67NR cells formed substantial 210 
pulmonary metastases in all three mice.  211 
 Finally, in a more stringent metastasis experiment, control and Kdm3a knockdown 4T07 212 
cells (Figure 4–figure supplement 7), a non-metastatic mouse breast cancer cell line, were 213 
injected in the mammary fat pad of ten syngeneic mice. After 22 days the primary tumors were 214 
surgically removed and 8 weeks post-injection the animals were sacrificed and pulmonary 215 
tumors quantified. The growth of primary tumors formed by NS or Kdm3a knockdown cells was 216 
similar (Figure 4H and Figure 4–figure supplement 8). However, Kdm3a knockdown cells 217 
caused significantly increased metastatic burden in the lungs compared to control 4T07 cells 218 
(Figure 4I and Figure 4–figure supplement 9). Consistent with our results, knockdown of Bnip3 219 
has also been shown to cause increased metastasis in similar in vivo experiments (Manka et al., 220 
2005). Collectively, these results show that KDM3A functions to prevent metastasis.  221 
Based on the results presented above, we propose a model of anoikis induction that is 222 
illustrated in Figure 3G and discussed below. Following detachment of non-transformed cells, 223 
integrin signaling is decreased leading to transcriptional induction of KDM3A. The increased 224 
levels of KDM3A results in its recruitment to the pro-apoptotic genes BNIP3 and BNIP3L, where 225 
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it promotes demethylation of inhibitory H3K9me1/2 marks and transcriptional activation of the 226 
two genes, resulting in anoikis induction. Consistent with this model, previous studies have 227 
shown that hypoxia results in transcriptional activation of KDM3A, BNIP3 and BNIP3L (Beyer et 228 
al., 2008; Sowter et al., 2001). We have found that in anoikis-resistant human breast cancer cell 229 
lines and tumors, KDM3A expression is defective, highlighting the importance of this pathway in 230 
promoting anoikis. Collectively, our results reveal a novel transcriptional regulatory program 231 
that mediates anoikis in non-transformed cells and is disabled during cancer development.  232 
As described above, previous studies have shown that BIM and BMF are also effectors of 233 
anoikis (Reginato et al., 2003; Schmelzle et al., 2007). However, we have found that unlike 234 
BNIP3 and BNIP3L, BIM and BMF are not regulated by KDM3A. Thus, our results reveal that 235 
anoikis is promoted by multiple non-redundant pathways, which may help prevent the 236 
development of anoikis resistance. 237 
  238 
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Material and Methods 239 
 240 
Cell lines and culture 241 
T47D, MDA-MB-231, BT549 and CLS1 cells were obtained from ATCC (Manassas, VA) and 242 
grown as recommended by the supplier. MCF7 cells (National Cancer Institute, Bethesda, MD) 243 
were maintained in DMEM (GE Healthcare Life Sciences, Marlborough, MA) supplemented 244 
with 1X nonessential amino acids (NEAA; Thermo Scientific, Waltham, MA) and 10% fetal 245 
bovine serum (FBS; Atlanta Biologics, Norcross, GA). MCF10A cells (ATCC) were maintained 246 
in DMEM/F12 (GE Healthcare Life Sciences) supplemented with 5% donor horse serum 247 
(Thermo Scientific), 20 ng/ml epidermal growth factor (Peprotech, Rocky Hill, NJ), 10 µg/ml 248 
insulin (Life Technologies, Grand Island, NY), 1 ng/ml cholera toxin (Sigma-Aldrich, St. Louis, 249 
MO), 100 µg/ml hydrocortisone (Sigma-Aldrich), 50 U/ml penicillin (Thermo Scientific), and 50 250 
µg/ml streptomycin (Invitrogen, Grand Island, NY). SUM149 cells were obtained from Dr. 251 
Donald Hnatowich (University of Massachusetts Medical School, Worcester, MA) and grown in 252 
RPMI (Invitrogen) supplemented with 10% FBS, 0.01% insulin, 50 U/ml penicillin, and 50 253 
µg/ml streptomycin. 67NR and 4T07 cells were obtained from Dr. Fred Miller (Wayne State 254 
University School of Medicine, Detroit, MI) and were grown in high glucose DMEM (GE 255 
Healthcare Life Sciences) supplemented with 10% FBS, 50 U/ml penicillin, and 50 µg/ml 256 
streptomycin. Cell lines used in this study have not been authenticated for identity. 257 
 258 
Ectopic expression 259 
KDM3A and KDM3A(H1120G/D1122N) were PCR amplified from pCMV-JMJD1A and 260 
pCMV-JMJD1A(H1120G/D1122N), respectively, obtained from Dr. Peter Staller (Biotech 261 
Research and Innovation Centre, University of Copenhagen, Denmark), using primers (forward, 262 
5’-CTCGAGCCGTTAAGGTTTGCCAAAAC-3’ and reverse, 5’-ATCGTTAACAGGGAGATT 263 
AAGGTTTGCCA-3’) engineered with XhoI and HpaI restriction sites and then cloned into 264 
pMSCVpuro (ClonTech Laboratories, Inc., Mountain View, CA). BNIP3L was PCR amplified 265 
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from Bnip3L pcDNA3.1 (plasmid #17467, Addgene, Cambridge, MA) using primers (forward, 266 
5’-AATCTCGAGCATGTCGTCCCACCTAGT-3’ and reverse 5’-ATCGAATTCTTAATAGGT 267 
GCTGGCAGAGG-3’) engineered with XhoI and EcoRI restriction sites and cloned into 268 
pMSCVhygro (ClonTech Laboratories, Inc.). BNIP3 was PCR amplified from MGC Human 269 
BNIP3 cDNA (Dharmacon, Marlborough, MA) using primers (forward, 5’-AATCTCGAGCAT 270 
GTCGCAGAACGGAGCG-3’ and reverse 5’- ATCGAATTCACTAAATTAGGAACGCAGC 271 
AT-3’) engineered with XhoI and EcoRI restriction sites and cloned into pMSCVpuro.  272 
 MCF10A cells stably expressing pMSCVpuro-JMJD1A, pMSCVpuro-JMJD1A-273 
H1120G/D1122N, pMSCVpuro-BNIP3, pMSCVhygro-BNIP3L, pMSCVpuro-empty, 274 
pMSCVhygro-empty, pBABE-MEK2DD (obtained from Dr. Sylvain Meloche, Universite de 275 
Montreal), pBABE-EGFR (Addgene), or pBABE-empty (Addgene) were generated by retroviral 276 
transduction as described previously (Santra et al., 2009). Twelve days after puromycin or 277 
hygromycin selection, cells were stained with 0.5% crystal violet.  278 
 279 
RNA interference  280 
The human shRNAmir pSM2 library (Open Biosystems/Thermo Scientific, Pittsburgh, PA) was 281 
obtained through the University of Massachusetts Medical School RNAi Core Facility 282 
(Worcester, MA). Retroviral pools were generated and used to transduce MCF10A cells as 283 
described previously (Gazin et al., 2007). Following puromycin selection, transduced cells were 284 
divided into two populations: one was plated on poly-HEMA-coated tissue culture plates (plates 285 
were coated with poly-HEMA (20 mg/ml) (Sigma-Aldrich), dried at room temperature 286 
overnight, and washed with phosphate buffered saline (PBS) before use) and grown for 10 days, 287 
and the other was grown for 10 days under normal tissue culture conditions. Cells that survived 288 
10 days in suspension (a time point at which >95% of cells transduced with the control NS 289 
shRNA were killed) were seeded under normal tissue culture conditions to expand the 290 
population. shRNAs present in the surviving suspension population and the attached population 291 
were identified by deep sequencing at the University of Massachusetts Medical School Deep 292 
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Sequencing Core Facility (Worcester, MA). The frequency of individual shRNAs in each sample 293 
was determined as described previously (Xie et al., 2012). The raw sequencing data have been 294 
uploaded to NCBI Gene Expression Omnibus and are accessible through GEO Series accession 295 
number GSE80144. 296 
 For stable shRNA knockdowns, 1x105 cells were seeded in a six-well plate to 50% 297 
confluency and subsequently transduced with 200 µl lentiviral particles expressing shRNAs 298 
(obtained from Open Biosystems/Thermo Scientific through the UMMS RNAi Core Facility, 299 
listed in Supplementary file 1) in a total volume of 1 ml of appropriate media supplemented with 300 
6 µg/ml polybrene (Sigma-Aldrich). Media was replaced after overnight incubation to remove 301 
the polybrene, and viral particles and cells were subjected to puromycin selection (2 µg/ml) for 3 302 
days. 303 
 304 
qRT-PCR 305 
Total RNA was isolated and reverse transcription was performed as described (Gazin et al., 306 
2007), followed by qRT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems, 307 
Grand Island, NY). RPL41 or GAPDH were used as internal reference genes for normalization. 308 
See Supplementary file 2 for primer sequences. Each sample was analyzed three independent 309 
times and the results from one representative experiment, with technical triplicates or 310 
quadruplicates, are shown. 311 
 312 
Anoikis assays 313 
Cells were placed in suspension in normal growth media in the presence of 0.5% methyl 314 
cellulose (Sigma Aldrich) (to avoid clumping of cells) on poly-HEMA-coated tissue culture 315 
plates. All anoikis assays were done at a cell density of 3x105 cells/ml. Control cells were 316 
cultured under normal cell culture conditions. Cell death was measured by staining the cells with 317 
FITC-conjugated Annexin-V (ApoAlert, ClonTech) according to the manufacturer’s instructions 318 
followed by analysis by flow cytometry (Flow Cytometry Core Facility, University of 319 
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Massachusetts Medical School) at the indicated times. To restore integrin signaling in 320 
suspension, media was supplemented with 5% growth-factor-reduced Matrigel (BD Biosciences, 321 
San Diego, CA). Each sample was analyzed in biological triplicate 322 
 323 
Immunoblot analysis 324 
Cell extracts were prepared by lysis in Laemmli buffer in the presence of protease inhibitor 325 
cocktail (Roche, Indianapolis, IN). The following commercial antibodies were used: beta-326 
ACTIN (Sigma-Aldrich); BNIP3, BNIP3L, KDM3A, H3K9me2 (all from Abcam, Cambridge, 327 
MA); cleaved Caspase 3, BIM, phospho-ERK1/2, total ERK1/2, phospho-EGFR, total EGFR, 328 
phospho-FAK (all from Cell Signaling Technology, Danvers, MA); total FAK (Millipore, 329 
Billerica, MA); and α-tubulin (TUBA; Sigma-Aldrich). 330 
 331 
Chemical Inhibitor Treatment 332 
Cells were treated with dimethyl sulfoxide (DMSO), 1, 5 or 10 µM U0126 (Cell Signaling 333 
Technology), gefitinib (Santa Cruz Biotechnology, Inc., Dallas, TX), or FAK inhibitor 14 (CAS 334 
4506-66-5, Santa Cruz Biotechnology, Inc.) for 48 hours prior to preparation of cell extracts or 335 
total RNA isolation, as described above.  336 
 337 
ChIP assays 338 
ChIP assays were performed as previously described (Gazin et al., 2007) using antibodies against 339 
KDM3A and H3K9me2 (both from Abcam) and H3K9me1 (Epigentek). ChIP products were 340 
analyzed by qPCR (see Supplementary file 2 for promoter-specific primer sequences). Samples 341 
were quantified as percentage of input, and then normalized to an irrelevant region in the genome 342 
(~3.2 kb upstream from the transcription start site of GCLC). Fold enrichment was calculated by 343 
setting the IgG control IP sample to a value of 1. Each ChIP experiment was performed three 344 
independent times and the results from one representative experiment, with technical duplicates, 345 
are shown.  346 
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 347 
Analysis of KDM3A expression in human breast cancer samples 348 
This study was approved by the institutional review boards at the University of Massachusetts 349 
Medical School (UMMS) and the Mayo Clinic. Total RNA from 24 breast cancer patient 350 
samples were obtained from Fergus Couch (Mayo Clinic, Rochester, MN) and total RNA from 351 
five normal breast samples were obtained from the University of Massachusetts Medical School 352 
Tissue and Tumor Bank Facility. KDM3A expression was measured by qRT-PCR in technical 353 
triplicates of each patient sample. Statistical analysis (unequal variance t-test) was performed 354 
using R, a system for statistical computation and graphics (Ihaka and Gentleman, 1996). The 355 
Oncomine Cancer Profiling Database (Compendia Bioscience, Ann Arbor, MI) was queried 356 
using the cancer type Breast Cancer and a threshold p-value of 0.05 to access Finak (Finak et al., 357 
2008), Sorlie (Sorlie et al., 2001), Zhao (Zhao et al., 2004) and TCGA (TCGA, 2011) datasets. 358 
Histograms depicting KDM3A gene expression in each sample, and the p value for the 359 
comparison of KDM3A expression between the groups, were obtained directly through the 360 
Oncomine software. 361 
 362 
Animal experiments 363 
All animal protocols were approved by the Institution Animal Care and Use Committee 364 
(IACUC). Animal sample sizes were selected based on precedent established from previous 365 
publications.  366 
 367 
In vivo anoikis assays 368 
CLS1 cells were stably transduced with either a NS or Kdm3a shRNA and selected with 2 µg/ml 369 
puromycin for 5 days. Stably transduced CLS1 cells (2x105) were injected into the tail vein of 4-370 
6 week old female BALB/c mice (Taconic Biosciences) (n=4 mice per shRNA). Two weeks post 371 
injection the lungs were harvested, dissociated into single cell suspension, and plated onto tissue 372 
culture plates. Transduced CLS1 cells were selected for by treating the dissociated lung cells 373 
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with 2 µg/ml puromycin. Surviving colonies were stained with crystal violet and quantified by 374 
counting. All experiments were performed in accordance with the Institutional Animal Care and 375 
Use Committee (IACUC) guidelines. 376 
 377 
Pulmonary tumor assay 378 
67NR cells were transduced with a NS or Kdm3a shRNA and selected with 2 µg/ml puromycin 379 
for 5 days. Stably transduced 67NR cells (2x105) were injected into the tail vein of 6-8 week old 380 
female BALB/c mice (n=3 mice per shRNA). Five weeks post injection, mice were given an 381 
intraperitoneal injection of D-Luciferin (100 mg/kg) (Gold Biotechnology, St. Louis, MO) and 382 
imaged on the Xenogen IVIS-100 (Caliper Life Sciences). Images were taken with Living Image 383 
software. All experiments were performed in accordance with the Institutional Animal Care and 384 
Use Committee (IACUC) guidelines. 385 
 386 
Spontaneous metastasis assays 387 
Female BALB/c mice (4-6 weeks) were purchased from Charles River Laboratories 388 
(Shrewsbury, MA). The mice were housed in facilities managed by the McGill University 389 
Animal Resources Centre (Montreal, Canada), and all animal experiments were conducted under 390 
a McGill University–approved Animal Use Protocol in accordance with guidelines established 391 
by the Canadian Council on Animal Care.  392 
 Spontaneous metastasis studies were carried out as previously described (Tabaries et al., 393 
2011). Briefly, 4T07 cells expressing a NS or Kdm3a shRNA were first tested for mycoplasma 394 
contamination and found to be negative. Cells were then harvested from subconfluent plates, 395 
washed once with PBS, and resuspended (5x103 cells) in 50 µl of a 50:50 solution of Matrigel 396 
(BD Biosciences) and PBS. This cell suspension was injected into the right abdominal mammary 397 
fat pad of BALB/c mice (n=10 mice per shRNA) and measurements were taken beginning on 398 
day 7 post-injection. Animals that did not develop a primary tumor were excluded from the 399 
study. Tumor volumes were calculated using the following formula: πLW2/6, where L is the 400 
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length and W is the width of the tumor. Tumors were surgically removed, using a cautery unit, 401 
once they reached a volume around 500 mm3, approximately 3 weeks post injection. Lungs were 402 
collected 8 weeks post-injection. Tumor burden in the lungs was quantified from four H&E 403 
stained step sections (200 µm/step). The number of lesions per section were counted using 404 
Imagescope software (Aperio, Vista, CA). 405 
 406 
Statistics 407 
All quantitative data were collected from experiments performed in at least triplicate, and 408 
expressed as mean ± standard deviation, with the exception of Figures 4H and 4I, which are 409 
expressed as mean ± SEM. Differences between groups were assayed using two-tailed Student’s 410 
t test, except where noted above. Significant differences were considered when P<0.05. 411 
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Figure Legends 537 
 538 
Figure 1. Identification of KDM3A as an anoikis effector in breast cancer epithelial cells. (A) 539 
Schematic of the design of the large-scale RNAi screen to identify anoikis effectors. (B) Cell 540 
death, monitored by annexin V staining, in MCF10A cells expressing a non-silencing (NS) 541 
shRNA and cultured attached to the matrix, or in detached cells (cultured in suspension for 96 h) 542 
expressing a NS shRNA or one of five candidate shRNAs. Error bars indicate SD. P value 543 
comparisons are made to the detached, NS shRNA control. **P<0.01. (C) Crystal violet staining 544 
of MCF10A cells expressing vector, KDM3A or the catalytically-inactive 545 
KDM3A(H1120G/D1122N) mutant. 546 
 547 
Figure 2. Detachment and loss of integrin and growth factor receptor signaling induces KDM3A 548 
expression. (A) Immunoblot monitoring KDM3A levels in attached MCF10A cells, or detached 549 
cells cultured in suspension for 4, 8 or 24 h. β-actin (ACTB) was monitored as a loading control. 550 
(B) qRT-PCR analysis monitoring KDM3A mRNA levels in attached MCF10A cells, or detached 551 
cells cultured in suspension for 24 h. Error bars indicate SD. **P<0.01. (C) Immunoblot 552 
monitoring levels of KDM3A and BIMEL in attached MCF10A cells or detached MCF10A cells 553 
cultured in suspension for 24 h and treated in the presence or absence of Matrigel. α-tubulin 554 
(TUBA) was monitored as a loading control. (D) Immunoblot monitoring levels of KDM3A, 555 
phosphorylated FAK (p-FAK) or total FAK (t-FAK) in MCF10A cells treated for 48 hours with 556 
0, 1, 5 or 10 µM FAK inhibitor. (E) Immunoblot monitoring levels of KDM3A and BIMEL in 557 
MCF10A cells expressing either vector, EGFR or MEK2DD and cultured as attached (A) or 558 
detached (D) cells grown in suspension for 24 h. (F) Immunoblot monitoring levels of KDM3A, 559 
phosphorylated EGFR (p-EGFR) or total EGFR (t-EGFR) in MCF10A cells treated for 48 hours 560 
with 0, 1, 5 or 10 µM gefitinib. (G) Immunoblot monitoring levels of KDM3A, phosphorylated 561 
ERK1/2 (p-ERK1/2) or total ERK1/2 (t-ERK1/2) in MCF10A cells treated for 48 hours with 0, 562 
1, 5 or 10 µM U0126.  563 
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 564 
Figure 3. KDM3A induces anoikis by transcriptionally activating BNIP3 and BNIP3L. (A) qRT-565 
PCR analysis monitoring expression of pro-apoptotic BCL2 genes in detached MCF10A cells 566 
grown in suspension for 24 h and expressing a NS or KDM3A shRNA. The expression of each 567 
gene is shown relative to that obtained in attached cells expressing a NS shRNA, which was set 568 
to 1. P value comparisons for each gene are made to the NS shRNA control. Genes whose 569 
expression is decreased >2-fold upon KDM3A knockdown are indicated in red. (B) Immunoblot 570 
analysis monitoring levels of BNIP3 and BNIP3L in attached MCF10A cells, and detached cells 571 
following growth in suspension for 4, 8 or 24 h. (C) ChIP monitoring binding of KDM3A on the 572 
promoters of BNIP3 and BNIP3L or a negative control region (NCR) in attached MCF10A cells 573 
or detached cells grown in suspension for 24 h. P value comparisons for each region are made to 574 
the attached control. (D) ChIP monitoring the levels of H3K9me2 on the promoters of BNIP3 575 
and BNIP3L or a negative control region in attached MCF10A cells or detached cells expressing 576 
a NS or KDM3A shRNA and grown in suspension for 24 h. P value comparisons for each region 577 
are made to the detached, NS shRNA control. (E) Cell death, monitored by annexin V staining, 578 
in MCF10A cells expressing a NS, BNIP3 or BNIP3L shRNA. (F) Crystal violet staining of 579 
MCF10A cells expressing vector, BNIP3, BNIP3L or both BNIP3 and BNIP3L. (G) Model. 580 
Error bars indicate SD. *P<0.05; **P<0.01. 581 
 582 
Figure 4. KDM3A prevents metastasis and its expression is defective in human breast cancer cell 583 
lines and tumors. (A) Cell death, monitored by annexin V staining, in MCF10A cells and a panel 584 
of human breast cancer cell lines cultured as attached cells or detached following growth in 585 
suspension for 96 h. Error bars indicate SD. P value comparisons for each breast cancer cell line 586 
are made to the detached MCF10A sample. (B) Immunoblot analysis monitoring KDM3A levels 587 
in MCF10A cells and a panel of human breast cancer cell lines cultured as attached (A) cells or 588 
detached (D) following growth in suspension for 24 h. All images for the KDM3A antibody were 589 
cropped from the same blot and thus were processed and exposed in the same manner, as were 590 
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images for the TUBA loading control. (C) qRT-PCR analysis monitoring KDM3A expression in 591 
MCF10A cells and a panel of human breast cancer cell lines cultured as attached cells or 592 
detached following growth in suspension for 24 h. Error bars indicate SD. P value comparisons 593 
for each breast cancer cell line are made to the detached MCF10A sample. (D) Crystal violet 594 
staining of human breast cancer cells expressing vector, KDM3A or 595 
KDM3A(H1120G/D1122N). (E) qRT-PCR analysis monitoring KDM3A expression in normal 596 
breast epithelial cells and human breast tumors. TN, triple negative [estrogen receptor-negative 597 
(ER-), human epidermal growth factor receptor 2-negative (HER2-) and progesterone receptor-598 
negative (PR-)]. Error bars indicate SD. The differences in KDM3A expression between subtypes 599 
are not statistically significant. (F) Mouse pulmonary survival assay. (Left) Representative plates 600 
showing colony formation of CLS1 cells expressing a NS or Kdm3a shRNA that had been 601 
isolated from mouse lungs following tail vein injection. (Right) Quantification of colony 602 
formation (n=4 mice per shRNA). Error bars indicate SD. (G) Live animal imaging monitoring 603 
lung tumor metastasis in mice following injection of 67NR cells expressing a NS or Kdm3a 604 
shRNA (n=3 mice per group). (H) Primary tumor growth in mice injected with 4T07 cells 605 
expressing a NS (n=7) or Kdm3a (n=8) shRNA. Error bars indicate SEM. The differences in 606 
primary tumor growth between groups are not statistically significant. (I) Metastatic burden. 607 
Number of metastatic lesions per lung in mice injected with 4T07 cells expressing a NS (n=7) or 608 
Kdm3a (n=8) shRNA. Error bars indicate SEM. **P<0.01. 609 
  610 
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Figure supplement legends 611 
 612 
Figure 1–figure supplement 1. FACS analysis. Representative FACS plots corresponding to 613 
Figure 1B. 614 
 615 
Figure 1–figure supplement 2. Confirmation of the results of Figure 1B using a second, 616 
unrelated shRNA. (A) Cell death, monitored by annexin V staining, in MCF10A cells expressing 617 
a non-silencing (NS) shRNA and cultured attached to the matrix, or in detached cells (cultured in 618 
suspension for 96 h) expressing a NS shRNA or one of five candidate shRNAs unrelated to those 619 
used in Figure 1B. Error bars indicate SD. **P<0.01. (B) Representative FACS plots 620 
corresponding to (A). 621 
 622 
Figure 1–figure supplement 3. Analysis of BIM and candidate shRNA knockdown efficiencies. 623 
qRT-PCR analysis monitoring knockdown efficiencies of BIM and two unrelated shRNAs 624 
directed against the five candidate genes in MCF10A cells. Error bars indicate SD. *P<0.05; 625 
**P<0.01. 626 
 627 
Figure 1–figure supplement 4. Confirmation of increased levels of KDM3A upon ectopic 628 
expression. Immunoblot analysis monitoring levels of KDM3A in MCF10A cells expressing 629 
vector, KDM3A or KDM3A(H1120G/D1122N). The results confirm increased expression of 630 
KDM3A in cells transfected with KDM3A-expressing plasmids. α-tubulin (TUBA) was 631 
monitored as a loading control.  632 
 633 
Figure 2–figure supplement 1. Inhibition of FAK, EGFR, or MEK in MCF10A cells increases 634 
KDM3A expression. (A-C) qRT-PCR analysis monitoring KDM3A expression in MCF10A cells 635 
treated for 48 hours with 0, 1, 5 or 10 µM FAK inhibitor (A), gefitinib (B), or U0126 (C). Error 636 
bars indicate SD. **P<0.01.  637 
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 638 
Figure 3–figure supplement 1. Confirmation of the results of Figure 3A using a second, 639 
unrelated KDM3A shRNA. qRT-PCR analysis monitoring expression of BCL2 pro-apoptotic 640 
genes in detached MCF10A cells expressing a NS or a second, unrelated KDM3A shRNA to that 641 
used in Figure 3A. The expression of each gene is shown relative to that obtained in attached 642 
cells, which was set to 1. Error bars indicate SD. *P<0.05; **P<0.01. 643 
 644 
Figure 3–figure supplement 2. The level of H3K9me1 on the BNIP3 and BNIP3L promoters is 645 
diminished following detachment, which is counteracted by knockdown of KDM3A. ChIP 646 
monitoring the levels of H3K9me1 on the promoters of BNIP3 and BNIP3L or a negative control 647 
region (NCR) in attached MCF10A cells or detached cells expressing a NS or KDM3A shRNA 648 
and grown in suspension for 24 h. P value comparisons for each region are made to the detached, 649 
NS shRNA control. Error bars indicate SD. *P<0.05; **P<0.01.  650 
 651 
Figure 3–figure supplement 3. Overexpression of KDM3A, but not 652 
KDM3A(H1120G/D1122N), in attached MCF10A cells results in decreased levels of H3K9me1 653 
and H3K9me2 on the BNIP3 and BNIP3L promoters and increased expression of BNIP3 and 654 
BNIP3L. (A) ChIP monitoring the levels of H3K9me1, H3K9me2 and KDM3A on the promoters 655 
of BNIP3 and BNIP3L or a negative control region (NCR) in attached MCF10A cells expressing 656 
empty vector, wild-type KDM3A or KDM3A(H1120G/D1122N). The increased occupancy of 657 
KDM3A(H1120G/D1122N) on the BNIP3 and BNIP3L promoters is not unexpected because the 658 
mutations are in the catalytic domain and should not affect DNA binding. (B) qRT-PCR analysis 659 
monitoring expression of BNIP3, BNIP3L or KDM3A in attached MCF10A cells expressing 660 
empty vector, wild-type KDM3A or KDM3A(H1120G/D1122N). Error bars indicate SD. 661 
*P<0.05; **P<0.01. 662 
 663 
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Figure 3–figure supplement 4. Analysis of BNIP3 and BNIP3L shRNA knockdown 664 
efficiencies. qRT-PCR analysis monitoring knockdown efficiency of two unrelated BNIP3 and 665 
BNIP3L shRNAs in MCF10A cells. Error bars indicate SD. **P<0.01. 666 
 667 
Figure 3–figure supplement 5. Confirmation of the results of Figure 3E using a second, 668 
unrelated shRNA. (A) Cell death, monitored by annexin V staining, in MCF10A cells expressing 669 
a non-silencing (NS) shRNA or BNIP or BNIP3L shRNA unrelated to that used in Figure 3E. 670 
Error bars indicate SD. *P<0.05; **P<0.01. (B) Representative FACS plots corresponding to 671 
Figure 3E and (A). 672 
 673 
Figure 3–figure supplement 6. Confirmation of increased levels of BNIP3 and BNIP3L upon 674 
ectopic expression. Immunoblot analysis monitoring levels of BNIP3 or BNIP3L in MCF10A 675 
cells expressing vector, BNIP3 or BNIP3L. The results confirm increased expression of the 676 
proteins. α-tubulin (TUBA) was monitored as a loading control. 677 
 678 
Figure 4–figure supplement 1. FACS analysis. Representative FACS plots corresponding to 679 
Figure 4A. 680 
 681 
Figure 4–figure supplement 2. Oncomine analysis of KDM3A expression in breast cancer. The 682 
Oncomine Cancer Profiling database was queried to access Finak (A), Sorlie (B), Zhao (C) and 683 
The Cancer Genome Atlas (TCGA) (D) breast cancer data sets. The results reveal that KDM3A is 684 
significantly under-expressed in breast carcinoma relative to normal tissue. 685 
 686 
Figure 4–figure supplement 3. Analysis of basal KDM3A expression in human breast cancer 687 
cell lines. qRT-PCR analysis of KDM3A expression in MCF10A cells and a panel of human 688 
breast cancer cell lines cultured as attached cells. The results were normalized to that obtained in 689 
MCF10A cells, which was set to 1. The results show that basal KDM3A expression levels were 690 
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diminished in four of five human breast cancer cell lines analyzed. Error bars indicate SD. 691 
*P<0.05; **P<0.01. 692 
 693 
Figure 4–figure supplement 4. Analysis of Kdm3a shRNA knockdown efficiency in mouse 694 
CLS1 cells. qRT-PCR analysis monitoring knockdown efficiency of Kdm3a in CLS1 cells. Error 695 
bars indicate SD. **P<0.01. 696 
 697 
Figure 4–figure supplement 5. Analysis of Kdm3a expression in a mouse breast cancer 698 
carcinoma progression series. qRT-PCR analysis of Kdm3a expression in 67NR, 4T07, and  4T1 699 
cells. Error bars indicate SD. **P<0.01. 700 
 701 
Figure 4–figure supplement 6. Analysis of Kdm3a shRNA knockdown efficiency in mouse 702 
67NR cells. qRT-PCR analysis monitoring knockdown efficiency of Kdm3a in 67NR cells. Error 703 
bars indicate SD. **P<0.01. 704 
 705 
Figure 4–figure supplement 7. Analysis of Kdm3a shRNA knockdown efficiency in mouse 706 
4T07 cells. qRT-PCR analysis monitoring knockdown efficiency of two unrelated Kdm3a 707 
shRNAs in 4T07 cells. Error bars indicate SEM. *P<0.05. 708 
 709 
Figure 4–figure supplement 8. Confirmation of the results of Figure 4H using a second, 710 
unrelated shRNA. Primary tumor growth in mice injected with 4T07 cells expressing a NS (n=7) 711 
or Kdm3a (n=9) shRNA unrelated to that used in Figure 4H. Error bars indicate SEM. The 712 
differences in primary tumor growth between groups are not statistically significant. 713 
 714 
Figure 4–figure supplement 9. Confirmation of the results of Figure 4I using a second, 715 
unrelated shRNA. Number of metastatic lesions per lung in mice injected with 4T07 cells 716 
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expressing a NS (n=7) or Kdm3a (n=9) shRNA unrelated to that used in Figure 4I. Error bars 717 
indicate SEM. **P<0.01.  718 
 719 
Supplementary file titles 720 
Supplementary file 1. List of shRNAs obtained from Open Biosystems/Thermo Scientific. 721 
Supplementary file 2. List of primers used for qRT-PCR and ChIP. 722 
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Source data file titles 724 
Figure 1–Source Data 1. List of 26 shRNAs, and the target genes, whose abundance was 725 
significantly enriched >500-fold following detachment of MCF10A cells. 726 
Figure 1-Source Data 2. Source data for Figure 1B. 727 
Figure 2-Source Data 1. Source data for Figure 2B. 728 
Figure 3-Source Data 1. Source data for Figure 3A, C, D and E. 729 
Figure 4-Source Data 1. Source data for Figure 4A, C, E, F, H and I. 730 




